Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 26;1(2):137-142.
doi: 10.3233/BLC-150017.

Alvimopan in an Enhanced Recovery Program Following Radical Cystectomy

Zach Hamilton  1 , Will Parker  1 , Josh Griffin  2 , Tanner Isaacson  1 , Moben Mirza  1 , Hadley Wyre  1 , Jeffrey Holzbeierlein  1 , Eugene K Lee  1
Affiliations
Free PMC article

Alvimopan in an Enhanced Recovery Program Following Radical Cystectomy

Zach Hamilton et al. Bladder Cancer. .
Free PMC article

Abstract

Background: Radical cystectomy (RC) carries a high complication rate, including post-operative ileus. Alvimopan is an FDA approved peripherally acting μ-opioid receptor antagonist that has shown favorable results for improved recovery of gastro-intestinal function resulting in decreased hospital length of stay. Many enhanced recovery pathways (ERP) have been published demonstrating improved outcomes with decreased hospital stay and morbidity. Objective: We evaluated the addition of alvimopan to an ERP in patients undergoing RC. Methods: Patients undergoing RC at our institution during the implementation phase of alvimopan to our established ERP were retrospectively reviewed. Effect of alvimopan as it related to the use of nasogastric tubes, time to initiation of regular diet, and length of hospital stay was assessed using Chi-squared and Student's T-tests. Linear regression was performed for univariate analysis and binary logistic regression was performed as a multivariate assessment of the effect of alvimopan. Results: Between July 2011 and January 2013, 80 patients were identified who underwent RC under the ERP (34 alvimopan and 46 standard care). Age, sex, neoadjuvant chemotherapy, surgical technique (open vs. robotic), and type of urinary diversion were not different between groups. Alvimopan was associated with a reduction in mean time to regular diet (5.3 vs 4.1 days, p < 0.01) and a reduction in mean length of hospital stay (6.9 vs 5.7 days, p = 0.01). After controlling for other variables, alvimopan usage predicted for shorter time to regular diet and total hospital stay. Conclusions: Alvimopan may help to improve time to regular diet and decrease hospital stay in patients on an enhanced recovery pathway.

Keywords: Bladder cancer; alvimopan; enhanced recovery pathway; radical cystectomy.

PubMed Disclaimer

Figures

Fig.1
Fig.1
Time to initiation of regular diet stratified by treatment group.
Fig.2
Fig.2
Length of stay stratified by treatment group.
See this image and copyright information in PMC

References

    1. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–866. - PubMed
    1. Collaboration ABCAM-a: Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. European Urology 2005;48:202-5. discussion 205-6. - PubMed
    1. Lowrance WT, Rumohr JA, Chang SS, et al. Contemporary open radical cystectomy: Analysis of perioperative outcomes. The Journal of Urology. 1313;179:1318–1318. discussion 1318. - PubMed
    1. Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: A high-volume tertiary cancer center experience. European Urology. 2009;55:177–185. - PubMed
    1. Stimson CJ, Chang SS, Barocas DA, et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. The Journal of Urology. 2010;184:1296–1300. - PubMed